VK-2019 News - LARVOL Sigma

|||||||||| VK-2019 / Cullinan Oncology
Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies. (On Demand | Hall A; Poster Bd # 27) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3811;
P2
An MTD has not been yet established. Preliminary results indicate a decrease in EBV copy number and viral gene expression in latently infected tumor cells in some patients.

||||||||||  VK-2019 / The Wistar Institute, Stanford University
Enrollment open, Trial initiation date:  Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies (clinicaltrials.gov) -  Dec 16, 2021
P2, N=30, Recruiting,  Sponsor: Stanford University
Preliminary results indicate a decrease in EBV copy number and viral gene expression in latently infected tumor cells in some patients. Not yet recruiting --> Recruiting | Initiation date: Aug 2021 --> Dec 2021

||||||||||  VK-2019 / Cullinan Oncology
Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) -  Oct 19, 2020
P1/2, N=14, Terminated,  Sponsor: Cullinan Oncology, LLC
Not yet recruiting --> Recruiting | Initiation date: Aug 2021 --> Dec 2021 N=60 --> 14 | Trial completion date: Jun 2023 --> Aug 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Jun 2020; Lack of efficacy

||||||||||  VK-2019 / Cullinan Oncology
Enrollment closed:  Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) -  Jun 17, 2020
P1/2, N=60, Active, not recruiting,  Sponsor: Cullinan Apollo Corporation
N=60 --> 14 | Trial completion date: Jun 2023 --> Aug 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Jun 2020; Lack of efficacy Recruiting --> Active, not recruiting

||||||||||  VK-2019 / Cullinan Oncology
Trial completion date:  Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) -  Mar 30, 2020
P1/2, N=60, Recruiting,  Sponsor: Cullinan Apollo Corporation
Recruiting --> Active, not recruiting Trial completion date: Jan 2022 --> Jun 2023

||||||||||  VK-2019 / Cullinan Oncology
Enrollment open:  Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) -  Apr 8, 2019
P1/2, N=60, Recruiting,  Sponsor: Cullinan Apollo Corporation
Trial completion date: Jan 2022 --> Jun 2023 Not yet recruiting --> Recruiting

||||||||||  VK-2019 / Cullinan Oncology
Trial completion date, Trial primary completion date:  Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) -  Feb 28, 2019
P1/2, N=60, Not yet recruiting,  Sponsor: Cullinan Apollo Corporation
Not yet recruiting --> Recruiting Trial completion date: Dec 2025 --> Jan 2022 | Trial primary completion date: Dec 2024 --> Oct 2021

||||||||||  VK-2019 / Cullinan Oncology
New P1/2 trial:  Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) -  Sep 24, 2018
P1/2, N=50, Not yet recruiting,  Sponsor: Troy Messick



	Diseases Companies Products Productz Mechanisms of Action Sites